Brooks Laboratories Share Price
Small Cap | Pharmaceuticals and health care | NSE: BROOKS | BSE: 533543
₹101.55 
-0.79 (-0.77 %)
Last Updated: 13 Mar 2025 12:00 AM
BEARISH
Overview
Open (₹) 103.36
High (₹) 104.50
Low (₹) 100.00
Prev. Close (₹) 102.34
Volume 3,615
VWAP (₹) 99.12
ROCE (%) 3.56
Industry P/E 43.95
TTM P/E -14.55
P/B Ratio 4.07
Market Cap (₹) Cr.299.82
Dividend Yield (%)--
EPS (₹) -7.65
ROE-30.61%
Sales Growth (%) 25.76
Profit Growth (%)-105.51
Day Range
104.50104.50
52 Week Range
72.51202.80
Historical Returns
Returns (6M)
-36.49 %
Returns (1Y)
-5.71 %
Returns (3Y)
13.93 %
Returns (5Y)
428.63 %
Returns (6M)
-36.49 %
Returns (1Y)
-5.71 %
Returns (3Y)
13.93 %
Returns (5Y)
428.63 %
SWOT Analysis
- Effectively using its capital to generate profits - ROCE improved in the last year
- Company with Low Debt
- Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years
- Increasing Revenue every Quarter for the past 4 Quarters
- Price above the pivot point indicates bullish sentiment.
Technicals
Technical Rating
BEARISHRSI 41.57
MFI 38.11
ATR 12.59
Commodity Channel Index -141.72
ROC125 -18.64
ROC21 -33.48
Williams %R -99.03
Resistance & Support
| Type | Resistance 1 | Resistance 2 | Resistance 3 | PP | Support 1 | Support 2 | Support 3 |
|---|---|---|---|---|---|---|---|
| Current | 104.66 | 110.88 | 114.31 | 101.23 | 95.01 | 91.58 | 85.36 |
| Week Ago | 127.41 | 132.03 | 134.71 | 124.73 | 120.11 | 117.43 | 112.81 |
| Month Ago | 155.36 | 156.23 | 156.66 | 154.93 | 154.06 | 153.63 | 152.76 |
EMA & SMA
101.55
Current Price
Bullish Moving Averages
0
Bearish Moving Averages
20
5 Day 116.27
9 Day 118.55
10 Day 121.76
12 Day 126.59
14 Day 130.14
20 Day 138.40
26 Day 142.13
50 Day 157.56
100 Day 149.69
200 Day 127.55
Deals & Announcements
Bulk and Block Deals
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| ATUL RANCHAL | bulk | Sell | 14 Nov, 2024 | ₹137.40 | 2,00,000 | BSE |
| ARYAN MAHAJAN | bulk | Sell | 14 Nov, 2024 | ₹137.40 | 4,80,000 | BSE |
| RR FAMILY TRUST | bulk | Buy | 14 Nov, 2024 | ₹137.40 | 2,18,300 | BSE |
| RAGHAV VIJAY KAROL | bulk | Sell | 29 Jul, 2021 | ₹89.00 | 1,50,000 | BSE |
| KHUSHBOO DINESH BUTAIL | bulk | Buy | 29 Jul, 2021 | ₹89.00 | 1,50,000 | BSE |
Insider Trading
| Date | Name | Action | Avg. Price | Quantity | Deal Value |
|---|---|---|---|---|---|
| 17 Nov, 2024 | Atul Ranchal | Disposal | ₹136.40 | 3,95,011 | BSE |
| 17 Nov, 2024 | Saras Gupta | Disposal | ₹137.40 | 1,15,404 | BSE |
| 17 Nov, 2024 | Aryan Mahajan | Disposal | ₹137.40 | 4,80,000 | BSE |
| 17 Nov, 2024 | Atul Ranchal | Disposal | ₹137.40 | 2,00,000 | BSE |
| 31 Aug, 2023 | Selina Ranchal Revised | Acquisition | ₹75.00 | 46,868 | BSE |
| 31 Aug, 2023 | Aryan Mahajan Revised | Acquisition | ₹75.00 | 70,970 | BSE |
| 31 Aug, 2023 | Davinder Kumari Revised | Acquisition | ₹75.00 | 4,698 | BSE |
| 31 Aug, 2023 | Davinder Kumari | Acquisition | ₹10.00 | 4,698 | BSE |
| 31 Aug, 2023 | Selina Ranchal | Acquisition | ₹10.00 | 46,868 | BSE |
| 31 Aug, 2023 | Savvy Ranchal | Acquisition | ₹10.00 | 90,952 | BSE |
Corporate Actions
| Announcement Date | Subject | Ex - Date | Record Date |
|---|---|---|---|
| 25 Jan, 2023 | Rights issue of equity shares of Rs. 10/- in the ratio of 1:16 @ premium of Rs. 65/-. | 28 Jul, 2023 | 28 Jul, 2023 |
Announcements
| Date | Source | Detail |
|---|---|---|
| 07 Mar, 2025 | NSE India | The Exchange had sought clarification from Brooks Laboratories Limited for the quarter ended 31-Dec-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results submitted is not as per format prescribed under Schedule III of the Companies Act, 2013. The response of the Company is enclosed. |
| 04 Mar, 2025 | NSE India | The Exchange has sought clarification from Brooks Laboratories Limited for the quarter ended 31-Dec-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed under Schedule III of the Companies Act, 2013. The response of the Company is awaited. |
| 28 Feb, 2025 | BSE India | Revision of Integrated Filing (Financial) for the quarter and nine months ended 31st December 2024. |
| 28 Feb, 2025 | BSE India | Revision of Integrated Filing (Financial) for the quarter and nine months ended 31st December 2024. |
| 28 Feb, 2025 | NSE India | Brooks Laboratories Limited has informed the Exchange about General Updates Integrated Filing (Financial) for the quarter and nine months ended 31st December, 2024 (Revised). |
| 25 Feb, 2025 | BSE India | Revision of the outcome of the Board Meeting held on 13th February 2025. |
| 25 Feb, 2025 | NSE India | Brooks Laboratories Limited has informed the Exchange regarding, revision in outcome of the Board Meeting held on 13th February 2025. |
| 14 Feb, 2025 | NSE India | Brooks Laboratories Limited has informed the Exchange about Copy of Newspaper Publication for Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended 31st December 2024. |
| 13 Feb, 2025 | NSE India | Integrated Filing (Financial) for the quarter and nine months ended December 31, 2024 |
| 13 Feb, 2025 | BSE India | Integrated Filing (Financial) for the quarter and nine months ended 31st December 2024. |
Board Meetings
| Purpose | Details | Meeting Date | Broadcast Date |
|---|---|---|---|
| Quarterly Results | -- | 11 Feb, 2025 | 13 Feb, 2025 |
| To consider Fund Raising & Others | Inter-alia, to consider and approve 1. Proposal for Raising Funds through the issuance of securities (Equity Shares) by way of a preferential issue. 2. To approve the EGM. 3. Other business matters. | 17 Dec, 2024 | 11 Dec, 2024 |
| Quarterly Results | -- | 07 Nov, 2024 | 09 Nov, 2024 |
| Quarterly Results | -- | 07 Aug, 2024 | 14 Aug, 2024 |
| Audited Results | -- | 14 May, 2024 | 18 May, 2024 |
| Quarterly Results | -- | 25 Jan, 2024 | 31 Jan, 2024 |
| Rights & Preferential issue | -- | 19 Jan, 2024 | 24 Jan, 2024 |
| Quarterly Results | -- | 02 Nov, 2023 | 09 Nov, 2023 |
| Quarterly Results | -- | 03 Aug, 2023 | 10 Aug, 2023 |
| Rights issue of Equity Shares | -- | 12 Jul, 2023 | 18 Jul, 2023 |
Share Holding Pattern
| Owner Name | Jan, 2025 | Dec, 2024 | Sept, 2024 | Jun, 2024 | Mar, 2024 |
|---|
About Brooks Laboratories
Brooks Laboratories is a Public Limited Listed company incorporated on 23/01/2002 and has its registered office in the State of Himachal Pradesh, India. Company’s Corporate Identification Number(CIN) is L24232HP2002PLC000267 and registration number is 000267. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 79.49 Cr. and Equity Capital is Rs. 26.25 Cr. for the Year ended 31/03/2024. Read More
Parent Organisation
Not Applicable
Founded
2002
Managing Director
-- --
NSE Symbol
BROOKS
Brooks Laboratories Management
| Name | Designation |
|---|---|
| Ms. Sonia Gupta | Independent Director |
| Mr. Jitendra Pratap Singh | Whole Time Director |
| Mr. Durga Shankar Maity | Whole Time Director |
| Mr. Bhushan Singh Rana | Whole Time Director |
| Mr. Lalit Mahajan | Addnl.Independent Director |
| Dr. Usha Singh | Addnl.Independent Director |
Peer Comparison
| Stocks | Market Cap | Market Price | 52 Week Low-High |
|---|---|---|---|
| Sun Pharmaceutical Industries | ₹4,03,916.05 | ₹1,683.45  ₹1,676.85(0.39%) | ₹1,376.750 - ₹1,960.200 |
| Divi's Laboratories | ₹1,49,205.29 | ₹5,620.45  ₹5,667.15(-0.82%) | ₹3,350.050 - ₹6,448.750 |
| Cipla | ₹1,18,065.23 | ₹1,461.90 ₹1,454.30(0.52%) | ₹1,317.600 - ₹1,702.000 |
| Torrent Pharmaceuticals | ₹1,03,430.62 | ₹3,056.05 ₹3,096.50(-1.31%) | ₹2,488.000 - ₹3,589.950 |
| Dr. Reddy's Laboratories | ₹92,453.48 | ₹1,107.95 ₹1,105.15(0.25%) | ₹1,093.000 - ₹1,420.200 |
FAQs on Brooks Laboratories
What is the share price of Brooks Laboratories?
The share price of Brooks Laboratories on 13 Mar, 2025 is ₹ 101.55.
What is 52W high and 52W low share price of Brooks Laboratories?
The highest and lowest 52W share prices of Brooks Laboratories are ₹ 202.800 and ₹ 72.510
What is the market cap of Brooks Laboratories?
The market capitalization of Brooks Laboratories as of 13 Mar, 2025 is ₹ 299.82 Crores
What is the P/E ratio of Brooks Laboratories?
The current P/E ratio of Brooks Laboratories as of 13 Mar, 2025 is 43.95
What is the PB ratio of Brooks Laboratories?
The PB ratio of Brooks Laboratories as of 13 Mar, 2025 is 4.07
Top Gainers
₹41.02
₹34.29 (0.20%)
₹8.84
₹7.37 (0.20%)
₹6.97
₹5.81 (0.20%)
₹194.70
₹162.25 (0.20%)
Top Losers
₹13.75
₹135.15 (-0.90%)
₹9.60
₹12.00 (-0.20%)
₹9.80
₹93.55 (-0.90%)
₹0.99
₹4.77 (-0.79%)
Market Indices
Sensex
₹73,828.91
₹74,029.76 (0.00%)